Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 26, 2020

Filing Date
Filed February 17, 2021
Period End
December 26, 2020
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-K filed February 17, 2021. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. (NYSE: CRL) reported fiscal 2020 total revenue of $2.92 billiona, up from $2.62 billion in 2019, an increase of $302.7 million, or 11.5%.

Growth was driven mainly by the Discovery and Safety Assessment (DSA) segment, whose revenue rose $218.4 millionb, or 13.5%, to $1.84 billion, and by Manufacturing Support, which rose 10.8% to $515.4 million. Research Models and Services (RMS) revenue rose 6.3% to $571.1 million, but its operating income fell 23.3% to $102.7 million as COVID-19 reduced demand for research models in the second quarter. Consolidated operating income rose 23.2% to $432.7 million, and net income attributable to common shareholders increased to $364.3 million from $252.0 million, helped by $100.9 million of net gains on venture capital and strategic equity investments.

Cash flow from operations was $546.6 millionc, compared with $480.9 million in 2019. Total debt and finance leases were $2.0 billion at December 26, 2020, and the company had $129.1 million remaining under its stock repurchase program, with no repurchases in fiscal 2020. The filing states the company does not expect to pay cash dividends in the foreseeable future.

Acquisitions in 2020 included HemaCare and Cellero, and the company signed an agreement on February 17, 2021 to acquire Cognate BioServices, Inc. for approximately $875 milliond in cash, expected to close by the end of the first quarter of 2021 and to be financed with cash and Credit Facility borrowings. Risk factors highlighted by the filing include the continuing COVID-19 pandemic, dependence on limited sources of large research models (with China supplying a significant portion of certain critical models), the financial risk of contracts that may be terminated or underpriced, cybersecurity (including a March 2019 unauthorized access incident), and LIBOR phase-out affecting the credit facility that matures in fiscal 2023.

Key Highlights

  1. Fiscal 2020 total revenue of $2.92 billion, up 11.5% from $2.62 billion, with DSA revenue up 13.5% to $1.84 billion.
  2. Operating income rose 23.2% to $432.7 million, with operating margin of 14.8% versus 13.4% in 2019.
  3. RMS operating income fell 23.3% to $102.7 million as COVID-19 reduced research model demand, while RMS revenue still grew 6.3%.
  4. Net income attributable to common shareholders increased to $364.3 million, aided by $100.9 million of net gains on venture capital and strategic equity investments.
  5. Operating cash flow was $546.6 million, up from $480.9 million, and total debt and finance leases were $2.0 billion at year-end.
  6. Agreed on February 17, 2021 to acquire Cognate BioServices, Inc. for approximately $875 million in cash, expected to close by the end of Q1 2021.
  7. The company did not repurchase shares in fiscal 2020 and had $129.1 million remaining under its stock repurchase authorization; it has not paid cash dividends.

Financial Statements

FY2020 against FY2019

Line itemFY2020FY2019Change
Revenue$2.92B$2.62B+11.5%
SG&A Expenses$528.93M$517.62M+2.2%
Operating Income$432.73M$351.15M+23.2%
Interest Expense$86.43M$60.88M+42.0%
Net Income$364.30M$252.02M+44.6%
EPS (Basic)$7.35$5.17+42.2%
EPS (Diluted)$7.20$5.07+42.0%
Shares Outstanding (Basic)49.55M48.73M+1.7%
Shares Outstanding (Diluted)50.61M49.69M+1.8%

Frequently Asked Questions

  1. How did Charles River perform financially in fiscal 2020?

    Total revenue rose 11.5% to $2.92 billion and operating income rose 23.2% to $432.7 million. Net income attributable to common shareholders was $364.3 million, compared with $252.0 million in 2019. The DSA and Manufacturing segments drove growth, while RMS revenue increased but its operating income declined due to COVID-19.

  2. What impact did COVID-19 have on the business?

    The filing says demand for research models declined sharply in the second quarter of 2020 as client facilities closed, which reduced RMS product revenue and operating income. Demand recovered in the third quarter. The filing states the DSA business was not significantly impacted, and that all operating sites remained open as of the date of the report.

  3. What is the Cognate BioServices acquisition?

    On February 17, 2021, the company agreed to acquire Cognate BioServices, Inc. for approximately $875 million in cash, subject to customary closing adjustments. Cognate is a cell and gene therapy CDMO. The transaction is expected to close by the end of the first quarter of 2021 and to be reported in the Manufacturing segment, financed through available cash and Credit Facility borrowings.

  4. How leveraged is the company and what are its debt obligations?

    As of December 26, 2020, the company had $2.0 billion of debt and finance leases. The Credit Facility includes a $814.8 million revolving balance and a $146.9 million term loan, with approximately $2.05 billion of aggregate borrowing capacity. The filing also lists $500 million of 5.5% Senior Notes due 2026 and $500 million of 4.25% Senior Notes due 2028. The Credit Facility matures in fiscal 2023 and is linked to LIBOR.

  5. Does the company pay dividends or repurchase shares?

    The company has not declared or paid cash dividends and does not expect to pay dividends in the foreseeable future. It did not repurchase shares under its authorized program during fiscal 2020, leaving $129.1 million available. It acquired shares worth $24.0 million through the netting of stock for employee tax withholding.